Loading stock data…
$3.57-0.06 (-1.65%)
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
BCYC in the Healthcare sector is trading at $3.57. Wall Street consensus targets $9.50 (6 analysts), implying a +166.1% move over the next 12 months. The stock is currently near its 52-week low of $3.33, remaining 24.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $629,000↓ | $887,000↓ | $47.95M↑ | $11.73M↑ | $2.92M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$54.63M↑ | -$65.59M↓ | -$24.66M↑ | -$65.71M↑ | -$87.35M |
| Net Income | -$50.33M↑ | -$60.83M↓ | -$20.15M↑ | -$59.10M↑ | -$78.95M |
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenecti...